U.S. FDA Opposes Otsuka suit, Apotex Can Challenge Benicar Patents
This article was originally published in PharmAsia News
Executive Summary
FDA asks court to dismiss Otsuka’s Abilify suit; Apotex can seek infringement ruling on disclaimed Benicar patent; Apotex damages for omeprazole launch must be recalculated; hedge fund manager Kyle Bass files IPR petitions against Jazz and Shire.